Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Patric TeodorescuSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD; Universitatea de Medicina si Farmacie "Iuliu Hatieganu" Cluj-Napoca.
Sergiu PascaSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
InYoung ChoiSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Cynthia ShamsSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
W Brian DaltonSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Lukasz P GondekSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Amy E DeZernSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Gabriel GhiaurSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD. gghiaur1@jhmi.edu.
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6M
Targeting MRDP01CA225618 · NCI · JOHNS HOPKINS UNIVERSITY · PI Catherine M. Bollard · 2019 to 2026
$15.1M
Modeling myelodysplasiaR01CA253981 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI GRIMES, H. LEIGHTON, HALENE, STEPHANIE · 2021 to 2025
$2.9M
The Biological Consequences of Age-related Clonal HematopoiesisR01HL156144 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI GONDEK, LUKASZ PAWEL · 2021 to 2025
$2.0M
Biologic and Therapeutic Consequences of Distinct Hotspot SF3B1 Mutations in MDSR01HL159306 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI DALTON, WILLIAM BRIAN, DEZERN, AMY E · 2022 to 2025
$1.6M
CCRL2 as a Regulator of Growth and Novel Target in Myelodysplastic SyndromeK08HL168777 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Theodoros Karantanos · 2023 to 2026
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
An accessible patient-derived xenograft model of low-risk myelodysplastic syndromes. · full record | Socratic